Effect of liver pathophysiology on hepatic pharmacokinetics
Effect of liver pathophysiology on hepatic pharmacokinetics
批准号:
nhmrc : 252871
负责人:
Prof Darrell Crawford
金额:
$30.51万
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2003
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2003-01-01 至 2005-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The liver is the main organ in the body for the metabolism and biliary excretion of natural and foreign solutes. Various liver diseases such as cirrhosis, alcoholic liver disease, diet and drug induced fatty livers can affect the uptake and metabolism of drugs and their suitability- dosing needs. Some liver diseases such as fatty livers are very common but how rapidly drugs are metabolised in these patients is not well described. The work is important as it may help us better design new drugs and better choose which drugs to give and, if so, in what doses. In addition, many liver diseases require a biopsy for a definite diagnosis of the likely function of the liver. Estimation of liver function is particularly important in estimating whether there will be sufficient reserve on resection of a cancer or deciding if a liver transplant is needed. The liver is also a very complex organ which can trap or breakdown solutes by a range of different systems. Also of importance is how those diseases affect drug disposition in the liver given that an altered hepatic drug disposition may affect systemic response to the drugs and their metabolites. This work seeks to answer these questions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tissue ferritin is a damage-associated molecular pattern (DAMP) in inflammasome-induced inflammation associated with hepatic stellate cell activation and fibrogenesis in chronic liver disease.
-
批准号:nhmrc : GNT1142394
-
项目类别:Project Grants
-
资助金额:$78.36万
-
财政年份:2018
-
负责人:Prof Darrell Crawford
-
依托单位:
Tissue ferritin is a damage-associated molecular pattern (DAMP) in inflammasome-induced inflammation associated with hepatic stellate cell activation and fibrogenesis in chronic liver disease.
-
批准号:nhmrc : 1142394
-
项目类别:Project Grants
-
资助金额:$52.98万
-
财政年份:2018
-
负责人:Prof Darrell Crawford
-
依托单位:
Ferritin binding and signalling receptors in hepatic fibrogenesis.
-
批准号:nhmrc : GNT1064533
-
项目类别:Project Grants
-
资助金额:$50.16万
-
财政年份:2014
-
负责人:Prof Darrell Crawford
-
依托单位:
Tissue ferritin acts as a proinflammatory mediator of hepatic fibrosis in chronic liver disease via multiple receptors in hepatic stellate cells responsible for both binding and signalling.
-
批准号:nhmrc : 1064533
-
项目类别:Project Grants
-
资助金额:$51.87万
-
财政年份:2014
-
负责人:Prof Darrell Crawford
-
依托单位:
Advanced imaging to define hepatic & intestinal drug disposition in aging & liver diseases
-
批准号:nhmrc : 1049979
-
项目类别:Project Grants
-
资助金额:$50.82万
-
财政年份:2013
-
负责人:Prof Darrell Crawford
-
依托单位:
国内基金
海外基金
登录
查看更多内容
G蛋白偶联受体GPR110调控Lp-PLA2抑制非酒精性脂肪性肝炎的作用及机制研究
-
批准号:82370865
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:黄哲
-
依托单位:
生理/病理应激差异化调控肝再生的“蓝斑—中缝”神经环路机制
-
批准号:82371517
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:杨立群
-
依托单位:
“肠—肝轴”PPARα/CYP8B1胆汁酸合成信号通路在减重手术改善糖脂代谢中的作用与机制
-
批准号:82370902
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:田景琰
-
依托单位:
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
-
批准号:82370885
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨
-
依托单位:
巨噬细胞通过Piezo1感知组织硬度限制肝脏纤维化的作用机制研究
-
批准号:82371760
-
项目类别:面上项目
-
资助金额:52.00万元
-
批准年份:2023
-
负责人:王静
-
依托单位:
犬尿氨酸酶KYNU参与非酒精性脂肪肝进展为肝纤维化的作用和机制研究
-
批准号:82370874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘才智
-
依托单位:
CD27-CD28-CD8+T细胞调控儿童肝脏移植免疫耐受形成的作用和机制
-
批准号:82371791
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘永波
-
依托单位:
血液蛋白参与肝细胞衰老可逆性调控机制的研究
-
批准号:32070732
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:王敏君
-
依托单位:
肝受体类似物(Liver Receptor Homolog 1, LRH 1)在雌鼠生殖过程中的作用及其机制
-
批准号:31172040
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2011
-
负责人:张丛
-
依托单位:
亚硝酸钠对肝移植物缺血再灌注损伤的保护作用及其机制
-
批准号:81170416
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:李巍
-
依托单位: